Cipher Pharmaceuticals Partner Moberg Pharma AB Reports Topline Data in MOB-015 Phase 3 Study

Stock Information for Cipher Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders
Cipher Pharmaceuticals Reports First Quarter 2025 Results, and Announces $15 Million Debt Repayment
Cipher Pharmaceuticals Schedules Q1 2025 Earnings Release and Conference Call
Cipher Pharmaceuticals Announces Normal Course Issuer Bid, Including Intention to Utilize Block Purchases
Cipher Pharmaceuticals Secures Medicaid Step-Through Preferred Status for Natroba(TM) in the state of Illinois
Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results
Cipher Pharmaceuticals Schedules Q4 & Fiscal 2024 Earnings Release and Conference Call
Cipher Pharmaceuticals Reports Third Quarter 2024 Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.